氯维地平与硝普钠在急性主动脉夹层中的比较:一项回顾性病历审查
本研究为单中心回顾性病历审查,纳入14例急性主动脉夹层患者,比较氯维地平与硝普钠作为艾司洛尔辅助用药的降压效果。主要终点为启动艾司洛尔后达到患者特定目标收缩压的时间,氯维地平组1.68小时 vs 硝普钠组1.03小时(p=0.99),无显著差异。目标收缩压外正负偏移的曲线下面积(AUCSBPe)中位数氯维地平组206.9 vs 硝普钠组538.9 mm Hg∗min∗hr-1(p=0.11),无显著差异。氯维地平组每日费用1223.28美元 vs 硝普钠组7674.24美元(p<0.001),显著降低。作者认为氯维地平是较便宜的合理替代选择,但需进一步研究验证。
要点
- 在急性主动脉夹层以艾司洛尔为基础的治疗中,氯维地平与硝普钠达到目标收缩压的中位时间分别为1.68小时 vs 1.03小时(p=0.99),无显著差异。
- 目标收缩压外偏移的AUCSBPe中位数氯维地平组206.9 vs 硝普钠组538.9 mm Hg∗min∗hr-1(p=0.11),无显著差异。
- 氯维地平组每日费用1223.28美元 vs 硝普钠组7674.24美元(p<0.001),氯维地平显著降低费用。
- 作者认为氯维地平是急性主动脉夹层中艾司洛尔辅助治疗时较硝普钠更便宜的合理替代选择,但需进一步研究验证。
适用人群与场景
- 单中心回顾性病历审查纳入诊断为主动脉夹层的患者,最终分析14例。
处置流程与药物剂量
- 以艾司洛尔为基础治疗,氯维地平或硝普钠作为辅助血管扩张剂用于达到患者特定目标收缩压(SBPPT)。
研究设计与关键结果
- 研究类型为单中心回顾性病历审查,样本量14例,人群为主动脉夹层患者,干预为氯维地平 vs 硝普钠作为艾司洛尔辅助治疗。
- 启动艾司洛尔前中位收缩压:氯维地平组162 mm Hg vs 硝普钠组161 mm Hg(p=0.99)。
- 主要终点达到SBPPT目标的中位时间:氯维地平组1.68小时 vs 硝普钠组1.03小时(p=0.99),无显著差异。
- AUCSBPe中位数:氯维地平组206.9 vs 硝普钠组538.9 mm Hg∗min∗hr-1(p=0.11),无显著差异。
- 每日费用:氯维地平组1223.28美元 vs 硝普钠组7674.24美元(p<0.001),氯维地平显著降低。
证据类型、等级与局限
- 证据类型:单中心回顾性病历审查。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在急性主动脉夹层的初始内科治疗中,氯维地平作为艾司洛尔辅助治疗时疗效与硝普钠相似,是费用更低的合理替代选择;需进一步研究验证这些结果。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: Intravenous vasodilators are often added to beta-blocking agents to reach blood pressure (BP) goals in aortic dissection. Control of BP using clevidipine has been described in hypertensive emergencies and cardiac surgery but not in aortic dissection. The aim of this study was to compare clevidipine versus sodium nitroprusside (SNP) as adjunct agents to esmolol for BP management in aortic dissection.
METHODS: A single-center retrospective chart review evaluated patients diagnosed with aortic dissection. The primary outcome measure was time to reach patient specific systolic blood pressure (SBPPT) goals after initiation of esmolol infusion. Efficacy of clevidipine and SNP was assessed using area under the curve analysis of positive and negative excursions outside of SBPPT goals (AUCSBPe). Cost data was calculated using average wholesale price in U.S. dollars.
RESULTS: Fourteen patients were included in final analyses. Median systolic BP immediately prior to initiation of esmolol was 162mm Hg vs 161mm Hg for clevidipine and SNP groups, respectively (p=0.99). Median time to reach SBPPT goal was similar between clevidipine and SNP (1.68 versus 1.03h [p=0.99]). Median AUCSBPe was similar for clevidipine and SNP (206.9 versus 538.9 mm Hg∗min∗hr-1 [p=0.11]). Cost was significantly reduced using clevidipine versus SNP ($1223.28/day versus $7674.24/day [p<0.001]).
CONCLUSIONS: Clevidipine administration during initial medical management of aortic dissection showed similar efficacy compared to SNP when used as adjunct therapy to esmolol. These data suggest clevidipine is a less costly, reasonable alternative to SNP in acute aortic dissection as adjunct therapy to esmolol. Further studies are needed to validate these results.
参考来源
- Ulici A, Jancik J, Lam TS, et al. Clevidipine versus sodium nitroprusside in acute aortic dissection: A retrospective chart review. Am J Emerg Med. 2017. PMID: 28669696. doi:10.1016/j.ajem.2017.06.030
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。